Literature DB >> 29729119

Palliative care in end-stage liver disease: Time to do better?

Chiara Mazzarelli1,2, Wendy M Prentice3, Michael A Heneghan1, Luca S Belli2, Kosh Agarwal1, Mary D Cannon1.   

Abstract

Optimal involvement of palliative care (PC) services in the management of patients with decompensated cirrhosis and end-stage liver disease (ESLD) is limited. This may result from both ignorance and the failure to recognize the spectrum and unpredictability of the underlying liver condition. Palliative care is a branch of medicine that focuses on quality of life (QoL) by optimizing symptom management and providing psychosocial, spiritual, and practical support for both patients and their caregivers. Historically, palliative care has been underutilized for patients with decompensated liver disease. This review provides an evidence-based analysis of the benefits of the integration of palliative care into the management of patients with ESLD. Liver Transplantation 24 961-968 2018 AASLD.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh：

Year:  2018        PMID： 29729119     DOI： 10.1002/lt.25193

Source DB:  PubMed          Journal:  Liver Transpl        ISSN： 1527-6465            Impact factor:   5.799


  12 in total

Review 1.  Overview of Complications in Cirrhosis.

Authors:  Madhumita Premkumar; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2022-05-14

2.  LIVER TRANSPLANTATION: WILL XENOTRANSPLANTATION BE THE ANSWER TO THE DONOR ORGAN SHORTAGE?

Authors:  Robert L Carithers
Journal:  Trans Am Clin Climatol Assoc       Date:  2020

Review 3.  Palliative care in liver disease: what does good look like?

Authors:  Hazel Woodland; Ben Hudson; Karen Forbes; Anne McCune; Mark Wright
Journal:  Frontline Gastroenterol       Date:  2019-09-10

4.  Deaths from hepatocellular carcinoma are more likely to occur in medical facilities than deaths from other cancers: 2003-2018.

Authors:  Katie Truitt; Sadiya S Khan; Dyanna L Gregory; Sarah Chuzi; Lisa B VanWagner
Journal:  Liver Int       Date:  2021-05-11       Impact factor: 8.754

Review 5.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

Review 6.  Therapeutic Potential of HNF4α in End-stage Liver Disease.

Authors:  Ricardo Diaz-Aragon; Michael C Coard; Sriram Amirneni; Lanuza Faccioli; Nils Haep; Michelle R Malizio; Takashi Motomura; Zehra N Kocas-Kilicarslan; Alina Ostrowska; Rodrigo M Florentino; Carla Frau
Journal:  Organogenesis       Date:  2021-10-02       Impact factor: 2.316

7.  Guidelines on the management of ascites in cirrhosis.

Authors:  Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma
Journal:  Gut       Date:  2020-10-16       Impact factor: 23.059

8.  Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index.

Authors:  Yvonne Ayerki Nartey; Yaw Asante Awuku; Adwoa Agyei-Nkansah; Amoako Duah; Sally Afua Bampoh; Joshua Ayawin; Shadrack Osei Asibey; Niklas K Björkström; Weimin Ye; Mary Yeboah Afihene; Lewis Rowland Roberts; Amelie Plymoth
Journal:  BMC Gastroenterol       Date:  2020-12-26       Impact factor: 3.067

Review 9.  Adult stem cell transplantation combined with conventional therapy for the treatment of end-stage liver disease: a systematic review and meta-analysis.

Authors:  Chen-Hui Zhu; Dian-Han Zhang; Chen-Wei Zhu; Jing Xu; Chuan-Long Guo; Xiang-Gen Wu; Qi-Long Cao; Guo-Hu Di
Journal:  Stem Cell Res Ther       Date:  2021-10-30       Impact factor: 6.832

10.  Intensive care utilization in patients with end-stage liver disease: A population-based comparative study of cohorts with and without comorbid hepatocellular carcinoma in taiwan.

Authors:  Jen-Kuei Peng; Hao-Hsiang Chang; Irene J Higginson; Wei Gao
Journal:  EClinicalMedicine       Date:  2020-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.